Teva to Report First Quarter 2016 Financial Results on May 9, 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Guggenheim Remains Bullish Ahead of Teva Pharma's (TEVA) AGN Deal
April 18, 2016 11:38 AM EDTGuggenheim reiterated a Buy rating and $80.00 price target on Teva Pharma (NYSE: TEVA) ahead of a deal close and pipeline catalysts in 2016. The company's AGN generics deal is scheduled to close in June. Guggenheim Cut 2016 EPS estimates $0.35 to $5.17. The decreases in EPS estimates are... More
